Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study) Diego Casas Deza; Ana Belén Julián Gomara; Eva Caudevilla Biota; Belén Beltrán; Eugeni Domènech; Ana Gutiérrez Casbas; Miriam Mañosa; Yamile Zabana; Lourdes Roc Alfaro; Emilio Valverde Romero; Elena García González; Beatriz Sicilia; Viviana Laredo; Maria José Alcalá Escriche; Lucia Madero Velázquez; Rocío Ferreiro-Iglesias; Antonia Palmero Pérez; Margalida Calafat; Saioa Rubio Iturria; Irene Moraleja Yudego; Yolanda Ber Nieto; Sandra García Mateo; Javier P. Gisbert; Raquel Vicente Lidón; Lara Arias; Erika Alfambra; Ana Belén Doñate Borao; Elena Peña González; Pilar Corsino Roche; Miren Vicuña Arregui; Ainara Elorza; Manuel Domínguez Cajal; María Chaparro; Manuel Barreiro-de Acosta; Santiago García-López;

Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics Alicia Gonzalez-Martinez; Inés Muro; Sonia Quintas; María Chaparro; Javier P. Gisbert; Ancor Sanz-García; María José Casanova; Cristina Rubín de Célix; José Vivancos; Ana Beatriz Gago-Veiga;

Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy Edgar Castillo-Regalado; Raquel Ríos; Clàudia Aràjol; Cristina Gely; Lucía Márquez; Margalida Calafat; Carlos González-Muñoza; Fiorella Cañete; Francisco Mesonero; Jordi Guardiola; Esther Garcia-Planella; Míriam Mañosa; Eugeni Domènech;